Usage Examples
- Biocompatibility for the catheter was assessed as external communicating, blood path indirect, prolonged contact.
- We changed the mold release agent, so the biocompatibility evaluation has to be re-opened before the next lot ships.
- The deficiency is biocompatibility: they want a rationale for the omitted genotoxicity endpoint, not another cytotoxicity report.
What is Biocompatibility?
Biocompatibility is the property of a finished medical device to contact tissue, blood, or bone without provoking an unacceptable adverse biological response, evaluated for a defined contact category and duration rather than material by material.
Biocompatibility exists because a device material can be inert in a beaker and toxic in a patient. Polymers leach plasticizers, adhesives cure incompletely, sterilization leaves residuals, and a passivation step changes surface chemistry. No specification on a drawing predicts that. Biocompatibility is the regulatory mechanism that forces a manufacturer to demonstrate the finished article is safe in contact, not assume it.
Biocompatibility covers every device with direct or indirect body contact, categorized by contact type (surface, external communicating, implant) and duration, which together set the endpoints: cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, implantation, hemocompatibility, carcinogenicity. Biocompatibility stops at biological safety. It says nothing about mechanical strength, sterility assurance, electrical safety, or clinical performance; those are separate evaluations, with separate standards and separate reviewers.
Biocompatibility is applied as a written evaluation, not a stack of test reports. The reviewer wants a risk-based rationale: what the device contacts, for how long, which endpoints that triggers, which are addressed by testing, which by chemical characterization or a prior-use argument, and why each omission is justified. Biocompatibility deficiencies are usually gaps in that rationale, not failed tests.
Not to be confused with
- Biological evaluation
- the biological evaluation is the documented process; biocompatibility is the property it concludes about. FDA reviews the evaluation and its rationale, not a standalone "biocompatibility test result."
- ISO 10993-1
- ISO 10993-1 is the standard that structures the evaluation; biocompatibility is the outcome being demonstrated. Conforming to the standard is not the same as showing the device is biocompatible.
- Extractables and leachables testing
- E&L chemistry identifies what comes out of the material. Biocompatibility is the safety conclusion drawn from that chemistry plus biological testing and the device's contact context.
- Sterility
- sterility concerns living organisms on the device; biocompatibility concerns the device's own chemistry and physical form. A fully sterile device can still be cytotoxic, most often from residual sterilant.
The obligations come from the guidance FDA reviews against, the GLP rules governing the studies, and the quality system that keeps the evaluation current.
What you must do
- 1Conduct the biological evaluation within a risk management process, and document the rationale for every endpoint addressed and every endpoint omitted, before ordering any testFDA ISO 10993-1 Guidance (2023)
- 2Run the supporting safety studies under Good Laboratory Practice, because they support an application for a research or marketing permit for a medical device for human use21 CFR 58.1
- 3Treat prospective in vitro assays such as cytotoxicity and hemolysis as nonclinical laboratory studies rather than informal bench work, since the GLP definition covers in vitro experiments run to determine safety21 CFR 58.3
- 4Maintain the biological evaluation inside a quality management system meeting the QMSR, which since 2 February 2026 incorporates ISO 13485:2016 by reference21 CFR 820
- 5Re-open the evaluation on any change to material, supplier, process, adhesive, colorant, or sterilization method that could alter what contacts the patient21 CFR 820
Common mistakes
Testing the raw material instead of the finished device
A resin supplier's certificate describes pellets, not your molded, bonded, sterilized part. Sterilization residuals, mold-release agents, and adhesives are exactly where cytotoxicity shows up, and reviewers routinely reject material-level data as unrepresentative of the finished device.
Buying a test panel before writing the evaluation
Teams order a standard package, then find the contact category demanded endpoints they never ran, or paid for endpoints they never needed. The risk assessment defines the panel; reversing that order costs a full in vivo test cycle and a deficiency round.
Treating biocompatibility as a one-time deliverable
Any change to material supplier, molding process, adhesive, colorant, or sterilization method can invalidate the existing evaluation. If change control never asks the biocompatibility question, the file quietly stops describing the device you actually ship.
When This Matters
- Biocompatibility for the catheter was assessed as external communicating, blood path indirect, prolonged contact.
- We changed the mold release agent, so the biocompatibility evaluation has to be re-opened before the next lot ships.
- The deficiency is biocompatibility: they want a rationale for the omitted genotoxicity endpoint, not another cytotoxicity report.
Frequently Asked Questions
No. Biocompatibility evaluation is required only where the device has direct or indirect body contact; a non-contacting monitor or imaging console generally needs none. The trigger is contact with tissue, blood, or fluid paths, not device class, so a Class I skin-contact device can need more evaluation than a non-contacting Class II system.
Related Use Cases
- Medical Devices Use Cases
Prepare 510(k), PMA, and De Novo submissions with AI-guided pathway selection
- Consulting Use Cases
Manage 15+ client programs from one dashboard with per-client workspaces and tracking
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
Related Regulatory Intelligence
Related Actions
Sources & References
- FDA Guidance - Use of International Standard ISO 10993-1, Biological evaluation of medical devices
- FDA Biocompatibility Assessment Resource Center
- 21 CFR Part 58 - Good Laboratory Practice for Nonclinical Laboratory Studies (CFR full text)
- FDA Quality Management System Regulation (QMSR)
- ISO 10993-1:2018 - Biological evaluation of medical devices - Part 1
